PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
22.78%
Cost growth of 22.78% while CRVO maintains flat costs. Bruce Berkowitz would investigate efficiency gap.
-30.37%
Gross profit decline while CRVO shows 0.00% growth. Joel Greenblatt would examine competitive position.
-30.37%
Margin decline while CRVO shows 0.00% expansion. Joel Greenblatt would examine competitive position.
45.24%
R&D growth while CRVO reduces spending. John Neff would investigate strategic advantage.
-4.95%
G&A reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.69%
Operating expenses growth while CRVO reduces costs. John Neff would investigate differences.
24.69%
Total costs growth while CRVO reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
22.78%
D&A change of 22.78% while CRVO maintains D&A. Bruce Berkowitz would investigate efficiency.
-24.88%
EBITDA decline while CRVO shows 100.00% growth. Joel Greenblatt would examine position.
-24.88%
EBITDA margin decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
-24.83%
Operating income decline while CRVO shows 31.16% growth. Joel Greenblatt would examine position.
-24.83%
Operating margin decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
291.57%
Other expenses growth above 1.5x CRVO's 125.19%. Michael Burry would check for concerning trends.
-21.98%
Pre-tax income decline while CRVO shows 33.22% growth. Joel Greenblatt would examine position.
-21.98%
Pre-tax margin decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-17.79%
Net income decline while CRVO shows 33.22% growth. Joel Greenblatt would examine position.
-17.79%
Net margin decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
-12.12%
EPS decline while CRVO shows 33.12% growth. Joel Greenblatt would examine position.
-9.09%
Diluted EPS decline while CRVO shows 33.12% growth. Joel Greenblatt would examine position.
5.06%
Share count reduction below 50% of CRVO's 0.02%. Michael Burry would check for concerns.
6.04%
Diluted share reduction below 50% of CRVO's 0.02%. Michael Burry would check for concerns.